Xilio Therapeutics, Inc. (XLO)
Nasdaq · Healthcare · Biotechnology
$9.11+1.11%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $60.0M
- 52-week range
- $6.47 – $12.59
- 52-week change
- −21.99%
- EPS (trailing)
- −$0.60
Fiscal year to Dec 2025
- Revenue
- $43.8M (+589.88%)
- Net income
- −$35.0M
- Operating margin
- −95.9%
- Diluted EPS
- −$4.19
- Free cash flow
- −$5.5M
From the company’s annual report on SEC EDGAR.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 76 employees · xiliotx.com